Authors' Affiliations: Biochemistry, Molecular Biology and Biophysics Department; Masonic Cancer Center, University of Minnesota, Minneapolis; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research; Medical Genome Facility and Department of Laboratory Medicine and Pathology; Department of Laboratory Medicine and Pathology; Division of Medical Oncology, Department of Oncology; Division of Epidemiology, Department of Health Sciences Research; Division of Oncology Research, Department of Oncology; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic; Women's Cancer Program, Mayo Clinic Cancer Center, Rochester, Minnesota; Department of Cancer Biology, University of Kansas, Kansas City, Kansas; Department of Obstetrics & Gynecology, University of Washington School of Medicine, Seattle, Washington; and Illumina Cambridge Ltd, Chesterford Research Park, Little Chesterford, Cambridge, United Kingdom.
Cancer Res. 2013 Dec 15;73(24):7222-31. doi: 10.1158/0008-5472.CAN-13-1753. Epub 2013 Oct 23.
Ovarian cancer is a clinically and molecularly heterogeneous disease. The driving forces behind this variability are unknown. Here, we report wide variation in the expression of the DNA cytosine deaminase APOBEC3B, with elevated expression in the majority of ovarian cancer cell lines (three SDs above the mean of normal ovarian surface epithelial cells) and high-grade primary ovarian cancers. APOBEC3B is active in the nucleus of several ovarian cancer cell lines and elicits a biochemical preference for deamination of cytosines in 5'-TC dinucleotides. Importantly, examination of whole-genome sequence from 16 ovarian cancers reveals that APOBEC3B expression correlates with total mutation load as well as elevated levels of transversion mutations. In particular, high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5'-TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting that APOBEC3B-catalyzed genomic uracil lesions are further processed by downstream DNA "repair" enzymes including error-prone translesion polymerases. These data identify a potential role for APOBEC3B in serous ovarian cancer genomic instability.
卵巢癌是一种临床上和分子上具有异质性的疾病。这种变异性的驱动因素尚不清楚。在这里,我们报告了 DNA 胞嘧啶脱氨酶 APOBEC3B 的表达广泛变化,大多数卵巢癌细胞系(高于正常卵巢表面上皮细胞平均值三个标准差)和高级别原发性卵巢癌中表达升高。APOBEC3B 在几种卵巢癌细胞系的核内具有活性,并表现出对 5'-TC 二核苷酸中胞嘧啶脱氨的生化偏好。重要的是,对来自 16 个卵巢癌的全基因组序列的检查表明,APOBEC3B 的表达与总突变负荷以及转换突变的升高水平相关。特别是,高 APOBEC3B 表达与早期高级别浆液性卵巢癌基因组中 5'-TC 二核苷酸基序内的 C 到 A 和 C 到 G 转换突变相关,表明 APOBEC3B 催化的基因组尿嘧啶损伤进一步被下游 DNA“修复”酶(包括易错跨损伤聚合酶)加工。这些数据确定了 APOBEC3B 在浆液性卵巢癌基因组不稳定性中的潜在作用。